Ha respondido al tema Farmas USA
Creo haber leído que son acciones ordinarias que no salen al mercado, solo se emiten para la adquisición de DEPO mediante intercambio 0,95 a 1. Eso es lo que yo entiendo.
HZNP
Ir a respuesta
Todo
Foros
Blogs
Entidades
Productos
Expertos
Usuarios
Formación
Vídeos
Acceder
- Inicio
- Perfil de vilemos8
- Contenidos recomendados por vilemos8
Contenidos recomendados por vilemos8
Ha respondido al tema Farmas USA
Ir a respuesta
HZNP
Aprobada la emisión de 81.700.000 acciones ordinarias para la adquisición de DEPO
Horizon Pharma plc Provides Update on Shareholders Meeting Related to the Proposed Acquisition of Depomed, Inc.
Shareholders Approve the Issuance of up to 81,706,881 Ordinary Shares of Horizon Pharma plc in Connection With an Acquisition of Depomed, Inc.; Extends Exchange Offer to Acquire Depomed
DUBLIN, IRELAND -- (Marketwired) -- 11/13/15 -- Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced that its shareholders have approved four of the five proposals put before them today at the extraordinary general meeting of Horizon Pharma shareholders (the "Shareholder Meeting"). Further details on the voting results for each of the proposals put before the shareholders at the Shareholder Meeting can be found on the Current Report on Form 8-K that Horizon Pharma intends to file with the Securities and Exchange Commission later today.
"Today's overall favorable vote by our shareholders demonstrates the confidence they have in our team's ability to build value through the potential acquisition of Depomed," said Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma plc. "We and other like-minded shareholders believe that a combination with Depomed is financially, operationally and strategically compelling and look forward to continued engagement with Depomed shareholders as we work towards achieving this important merger."
By obtaining the approval of its shareholders on key proposals, Horizon Pharma has satisfied another of the conditions to its outstanding exchange offer to acquire all of the outstanding shares of common stock of Depomed. However, the exchange offer remains conditioned on, among other things, the redemption or removal of certain poison pill rights that the Depomed board has the unilateral ability to remove and the tender of a majority of the total number of outstanding Depomed shares on a fully diluted basis.
Proposal four, which concerned powers under Irish law to issue beyond the previously-authorized 300 million shares for cash without first offering those shares to existing shareholders under pre-emptive rights and required 75 percent approval, received slightly less than the required "for" votes, but does not have any effect upon Horizon Pharma's current offer for Depomed.
In order to provide sufficient time to satisfy the remaining conditions to its exchange offer, Horizon Pharma today also announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Depomed to 5 p.m., Eastern Time, on November 30, 2015. The exchange offer was previously scheduled to expire 5 p.m., Eastern Time on November 20, 2015. The depository of the exchange offer has advised that, as of 9:00 a.m., Eastern Time on November 13, 2015, a total of approximately 10,404 shares of Depomed common stock were validly tendered and not properly withdrawn in the exchange offer.
Ahora falta que los accionistas de DEPO den su aprobación.
HZNP
Ha respondido al tema Farmas USA
Ir a respuesta
HZNP
Horizon Pharma plc Provides Comment on Express Scripts' Business Practices
DUBLIN, IRELAND -- (Marketwired) -- 11/11/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Express Scripts' business practices.
"Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for patients and respect for physicians," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "Express Scripts is not only a pharmacy benefit manager that has significant control over prescriptions that flow to specialty pharmacies, it also operates its own mail-order pharmacy and thus is a direct competitor of small, independent specialty pharmacies throughout the United States. This competitive role, in our view, creates a clear conflict of interest, as Express Scripts stands as both a pharmacy's overseer and competitor. In fact, Express Scripts' specialty pharmacy, Accredo Health Group, Inc., is the largest in the United States with more than 28 percent market share. Based on its Accredo ownership, it's not surprising that Express Scripts would target small, competitive independent specialty pharmacies in order to force those pharmacies from its network, attempt to dominate the U.S. specialty pharmacy medicine distribution channel and further boost its own profits at the expense of patients. As the New York Times reported on July 15, 2015, independent specialty pharmacies believe that insurers and pharmacy benefit managers funnel business to their own pharmacies, even if others may provide better service."
"Additionally, we currently have an agreement with Accredo to provide one of our important orphan medicines to patients, and contrary to the misperception that Express Scripts wishes to create, Accredo accounts for a larger percentage of our revenue than any other pharmacy. However, based on current and past business practices by Accredo and Express Scripts, including its recent $60 million fraud settlement with the U.S. Department of Justice, we are re-evaluating this relationship to determine how we can most appropriately and ethically serve our patients, their physicians and our shareholders," Walbert continued.
"Profiteering, particularly in the case of Express Scripts which recognized more than $38 billion in revenues from specialty and home-delivery services in 2014, and anti-competitive behavior has to stop because ultimately it's the patients who suffer and the impact on the patient is far reaching," Walbert added. "As Linden Care stated in its legal complaint, 'if Linden does not receive a stay pending a hearing, the termination will remain in effect, resulting in innocent patients potentially missing medications due to a physical inability to obtain them through other channels, experiencing withdrawal symptoms from narcotics or experiencing errors in taking medications, thereby placing their well-being in jeopardy.' This isn't the right thing to do for patients and as an industry that exists to serve the patient, we need to take a stand to ensure that regardless of the hurdles we face from pharmacy benefit managers, we continue to do whatever possible to ensure patients have access to the medicines their physicians prescribe."
Statement Previously Released on November 10, 2015
Our primary concern is for the patients who, based on the profit driven actions of Express Scripts, may be denied access to medicines that are prescribed by their physicians. We are committed to ensuring that regardless of these actions, patients will have access to the medicines they need.
Less than five percent of our net sales are from prescriptions that are filled by Linden Care and processed by Express Scripts. In addition, we have a diverse group of pharmacies that participate in our patient support program and no pharmacy that participates in our primary care patient support programs account for more than 13 percent of our net sales.
The notion that Linden Care is a so-called "captive pharmacy" of Horizon Pharma is entirely false. At best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors. As previously stated, all pharmacies that distribute Horizon branded medicines are fully independent. Horizon does not own or have an ownership stake in any pharmacy and does not possess an option to purchase any pharmacy. In addition, the relationship with these pharmacies is non-exclusive where each of these pharmacies may also fulfill prescriptions for other drug manufacturers.
The lawsuit filed by Express Scripts relates entirely to a previously disclosed dispute concerning a prior rebate agreement between the parties. As we previously disclosed approximately one year ago, we terminated the contract with Express Scripts after Express Scripts failed to live up to its contractual obligations. Indeed, after we notified Express Scripts of its breaches, Express Scripts made no effort to cure the breaches, let alone respond to our notice, within the contractual deadline to terminate the contract. The substantial majority of the monetary damages Express Scripts is seeking to recover are for prescriptions that occurred after the termination of the contract. We are still reviewing the allegations in the complaint but we believe the claims are without merit and we intend to vigorously defend ourselves.
In light of Express Scripts' actions, we will evaluate all legal and other remedies and options.
Este comunicado es de la 13,35 de hoy, y por lo que leo la guerra es entre Express Scripts y Horizon, veremos cómo termina
Ha respondido al tema Farmas USA
Ir a respuesta
Puede que se decida por cerrar el que dejó el 6/11 en 17,4 - 18,7 o que se vaya directamente a cerrar el que dejó el 22/09 en 28,7 - 27,7. Qui lo sa?. Personalmente prefiero que no deje nada pendiente.
HZNP
Ha respondido al tema Farmas USA
Ir a respuesta
Gracias Triskis. Eso es lo que quería, opiniones. Estoy muy tranquilo, puesto que llevo en el valor desde Enero de 2013 y mi precio objetivo aún está muy lejos. Con respecto a la opa, será lo que quieran los accionistas de DEPO, pero si yo me encontrara entre ellos no dudaría en aceptar la oferta.
HZNP
Ha respondido al tema Farmas USA
Ir a respuesta
On October 5, 2015, at the request of our Board of Directors, Jack Lief, our President, Chief Executive Officer and principal financial officer, retired from the company, including our Board, effective today.
Más bien parece que "lo retiran" a petición del Consejo de Administración
http://invest.arenapharm.com/secfiling.cfm?filingid=1628280-15-7552&CIK=1080709
ARNA
Ha respondido al tema Farmas USA
Recompradas en 21,22 las vendidas el día 01/09 a 29,25. Espero no haberme precipitado
HZNP
Ir a respuesta
Ha respondido al tema Farmas USA
Ir a respuesta
Buenas noticias y reflejándose en la cotización.
Horizon Pharma plc Receives Positive CHMP Opinion for RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Aje.
HRZP
http://ir.horizon-pharma.com/secfiling.cfm?filingid=1193125-15-327992&CIK=1492426
Ha respondido al tema Farmas USA
Cruzó como un bólido la media de 50 sesiones en 23,88 y se va directa a tapar el gap en 22,65, si ahí no se para se encenderá la luz roja.
HZNP
Ir a respuesta
Ha respondido al tema Farmas USA
No había leído tu post, pero creo que pensamos lo mismo. Y eso no es dar la brasa, es dar info y de la buena.
Ir a respuesta